The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 54.00
Ask: 55.00
Change: 1.00 (1.87%)
Spread: 1.00 (1.852%)
Open: 53.50
High: 55.00
Low: 53.50
Prev. Close: 53.50
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Investor Report

24 Nov 2023 09:30

RNS Number : 6106U
Geiger Counter Ltd
24 November 2023

Geiger Counter Limited Plc

Monthly Investor Report - November

The full monthly factsheet is now available on the Company's website and a summary can be found below.

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

Enquiries:

?

For the Investment Manager

CQS (UK) LLP

Craig Cleland

0207 201 5368

?

For the Company Secretary and Administrator

BNP Paribas S.A., Jersey Branch

Dean Plowman/Ann-Marie Pereira

01534 813 967/ 01534 709198

-----------------------------------------------------------------------

Fund Description

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sec

Portfolio Managers

Keith Watson and Robert Crayfourd

Key Advantages for the Investor

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

Key Fund Facts1

Total Gross Assets

£99.1m

Reference Currency

GBP

Ordinary Shares:

Net Asset Value

64.84p

Mid-Market Price

48.25p

Net gearing4

16.09%

Discount

(25.59%)

Ordinary Share and NAV Performance2

One Month

Three Months

One Year

Three Years

Five Years

(%)

(%)

(%)

(%)

(%)

NAV

0.96

42.88

24.48

317.51

219.72

Share Price

-7.21

24.52

-7.21

194.21

135.37

Commentary3

After the previous month's price jump, the spot U3O8 price made a modest further gain in

October, closing the month up 1.9% at $74.5/lb. While the uranium market price continued to

rise, the Fund NAV slipped marginally, consolidating 1% in October versus a sterling decline of 2.4% registered by the Solactive Uranium Pure Play Index. The funds NAV discount widened slightly over the month, close to the highest in 7 years, despite the strong performance and positive sector fundamentals. The fund bought back shares which was accretive to the NAV per share.

Strong performance contributions were made by US in-situ project developers, UEC and Ur-Energy which rose 22% and 14% respectively in sterling terms. The pull-back by Paladin and Iso Energy largely offset these gains with both stocks retracing 15% in sterling terms, giving back nearly half their prior month increases. Explorer Iso Energy's decline followed an all-share acquisition of Uranium Consolidated, which owns a portfolio of development assets, at the end of September and the subsequent equity issue to raise proceeds to pursue a larger exploration programme on its expanded portfolio. The Fund participated in the placing by Iso Energy, alongside the group's other largest shareholders NexGen, Energy Fuels and Mega Uranium.

Cameco's Q3 results showed that the group achieved a sales price of US$52.57/lb during the period, versus spot prices which remained above $55/lb. Following the rise in spot uranium prices, which exceeded US$70/lb at the end of the quarter, the group updated its expectations for its full year realised price of C$63.50/lb, or approximately US$47/lb when translated using the exchange rate at end-September. This is indicative of the drag effect of prior forward sales contract terms on its uranium mining revenues. Cameco's guidance for full year uranium deliveries was maintained at between 31-33Mlbs U3O8, of which around 29Mlbs per annum is already contracted for the five years.

Elsewhere, French state-owned uranium fuel supplier Orano announced plans to expand

capacity at its Tricastin processing facility. An investment of $1.8bn is being made to increase capacity at the Georges Besse II enrichment plant by more than 30% in recognition of western government's desire to reduce the risk of fuel disruption given Russia's dominant global position in this area. In addition, the European Council reached a tentative agreement to reform an EU electricity price mechanism. This may remove the requirement for France's state-owned utility EDF to sell over a third of its nuclear energy production at below market prices, which should now increase the company's motivation to expedite repairs and reconnect the remaining offline reactors to the grid.

Gross Leverage

(%)

Commitment Leverage

(%)

Geiger Counter Ltd

116

116

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

CQS (Hong Kong) Limited

3305 AIA Tower, 183 Electric Road, North Point, Hong Kong, China

T: +852 3920 8600 | F: +852 2521 3189

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DOCUSVWROKUAURA
Date   Source Headline
29th Apr 202412:45 pmRNSNet Asset Value(s)
29th Apr 202412:30 pmRNSShare Buyback
26th Apr 20242:15 pmRNSGCL MONTHLY FACT SHEET MARCH 2024
26th Apr 202412:15 pmRNSNet Asset Value(s)
26th Apr 202412:00 pmRNSShare Buyback
25th Apr 20242:45 pmRNSNet Asset Value(s)
25th Apr 20242:00 pmRNSShare Buyback
24th Apr 20242:40 pmRNSNet Asset Value(s)
24th Apr 20241:30 pmRNSShare Buyback
23rd Apr 20243:30 pmRNSNet Asset Value(s)
23rd Apr 20241:45 pmRNSShare Buyback
22nd Apr 20243:35 pmRNSNet Asset Value(s)
22nd Apr 20241:30 pmRNSShare Buyback
19th Apr 20242:35 pmRNSNet Asset Value(s)
18th Apr 20241:35 pmRNSNet Asset Value(s)
17th Apr 202412:20 pmRNSNet Asset Value(s)
16th Apr 20245:20 pmRNSNet Asset Value(s)
15th Apr 202412:50 pmRNSNet Asset Value(s)
12th Apr 20241:35 pmRNSNet Asset Value(s)
11th Apr 20241:15 pmRNSNet Asset Value(s)
10th Apr 20243:40 pmRNSNet Asset Value(s)
9th Apr 20241:25 pmRNSNet Asset Value(s)
8th Apr 20241:10 pmRNSNet Asset Value(s)
5th Apr 20242:05 pmRNSNet Asset Value(s)
4th Apr 20241:10 pmRNSNet Asset Value(s)
3rd Apr 20242:40 pmRNSNet Asset Value(s)
3rd Apr 20249:00 amRNSInvestment Manager Acquisition
2nd Apr 20243:50 pmRNSNet Asset Value(s)
28th Mar 20241:50 pmRNSNet Asset Value(s)
27th Mar 20241:00 pmRNSNet Asset Value(s)
27th Mar 20249:33 amRNSNotification to Shareholders - Subscription Rights
26th Mar 20242:55 pmRNSNet Asset Value(s)
25th Mar 20241:00 pmRNSNet Asset Value(s)
22nd Mar 20244:45 pmRNSPotential listing on the London Stock Exchange
22nd Mar 20241:15 pmRNSNet Asset Value(s)
21st Mar 20241:25 pmRNSNet Asset Value(s)
20th Mar 20242:30 pmRNSNet Asset Value(s)
19th Mar 20244:45 pmRNSNet Asset Value(s)
18th Mar 20241:45 pmRNSNet Asset Value(s)
15th Mar 202411:35 amRNSNet Asset Value(s)
14th Mar 202412:45 pmRNSNet Asset Value(s)
13th Mar 20242:15 pmRNSNet Asset Value(s)
12th Mar 20245:00 pmRNSAGM Statement - Results of AGM 2024
12th Mar 20241:00 pmRNSNet Asset Value(s)
11th Mar 20241:35 pmRNSNet Asset Value(s)
8th Mar 20242:45 pmRNSNet Asset Value(s)
7th Mar 20242:45 pmRNSNet Asset Value(s)
6th Mar 20241:40 pmRNSNet Asset Value(s)
5th Mar 20242:30 pmRNSNet Asset Value(s)
4th Mar 20241:30 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.